![]() ![]() ![]() In fact, as detailed more extensively below, at least one of those 14 ailments - virtually absent except for occasional cases in a limited number of states - barely registers as a disease in this country at all. While those mainstream laboratory tests narrowly focus on a handful of widespread conditions, singled out as relevant by government authorities, GenPap screens for about 20 different organisms (some of them viewed as harmless) linked to both common and rare disorders alike. By the time that GenPap hit the market, however, gynecologists had already spent decades effectively utilizing traditional pap smears and (if warranted) cheap supplemental tests to diagnose the most prevalent disorders suffered by the patients they treat. With that test, known as GenPap, Bio-Reference greatly expanded the scope of a routine screening tool used on more than 50 million American women each year. Three years ago, Bio-Reference Laboratories introduced an elaborate – and expensive – version of the standard pap smear that has since become a celebrated, if controversial, driver of growth for the company. Editor's note: The following story is the first article in a two-part investigative report on Bio-Reference Laboratories (NASDAQ: BRLI-OLD) see Part II.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |